State University of New York Downstate Medical Center
New York, NY
Not yet accepting
DREAMM-10
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 3